Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/3/2017
SIETES contiene 91704 citas

 
 
 1 a 20 de 362 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, for the CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115-24. [Ref.ID 101371]
2. Cita con resumen
Carvalho C, Machado Caetano J, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain 2016:13 de octubre. [Ref.ID 100899]
3. Cita con resumen
Garattini S. The European Medicines Agency is still too close to industry. BMJ 2016;353:i2412. [Ref.ID 100360]
4. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
5. Cita con resumen
Bannuru RR, McAlindon TE, Sullivan MC, Wong JB, Kent DM, Schmid CH. Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials.. Ann Intern Med 2015;163:365-72. [Ref.ID 99463]
6.Enlace a cita original
Anónimo. Managing osteoarthritis. Australian Prescriber 2015;38:115-9. [Ref.ID 99278]
7.Tiene citas relacionadas Cita con resumen
Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015;385:2017-117. [Ref.ID 99159]
8.Tiene citas relacionadas Cita con resumen
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, for the EXAMINE Investigators. Heart failure and mortality ocutcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76. [Ref.ID 99158]
9.Tiene citas relacionadas
Standl E, Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015;385:2022-4. [Ref.ID 99156]
10. Cita con resumen
Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJF, Rombach I, Brindley D, Savulescu J, Beard DJ, Carr AJ. Use of placebo controls in the evaluation of surgery: systematic review. BMJ 2014;348:g3253. [Ref.ID 98009]
11. Cita con resumen
Spence D. Bad medicine: restless legs syndrome. BMJ 2013;347:f7615. [Ref.ID 97178]
13.Tiene citas relacionadas
Ndebele P. The Declaration of Helsinki, 50 years later. JAMA 2013;310:2145-6. [Ref.ID 96601]
14.Tiene citas relacionadas Cita con resumen
Redberg RF. All placebos are not created equally. JAMA Intern Med 2013;173:1951. [Ref.ID 96596]
15.Tiene citas relacionadas Cita con resumen
Meissner K, Fässler M, Rücker G, Kleijnen J, Hróbjartsson A, Schneider A, Antes G, Linde K. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 2013;173:1941-51. [Ref.ID 96593]
16. Cita con resumen
Kessner S, Sprenger C, Wrobel N, Wiech K, Bingel U. Effect of oxytocin on placebo analgesia: a randomized study. JAMA 2013;310:1733-5. [Ref.ID 96416]
17.
Hull SC, Colloca L, Avins A, Gordon NP, Somkin CP, Kaptchuk TJ, Miller FG. Patients' attitudes about the use of placebo treatments: telephone survey. BMJ 2013;347:15. [Ref.ID 96122]
18. Cita con resumen
Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. Can Med Assoc J 2013;185:1393-401. [Ref.ID 96118]
19.
Morris K. Revising the Declaration of Helsinki. Lancet 2013;381:1889-90. [Ref.ID 95582]
20.Tiene citas relacionadas
Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. BMJ 2012;345:25-8. [Ref.ID 93567]
Seleccionar todas
 
 1 a 20 de 362 siguiente >>